As part of the University at Buffalo, we are dedicated to high quality academic research, with a focus on translational use of quantitative neuroimaging metrics in neurological diseases and disorders like MS, Alzheimer’s, and stroke. We have published over 500 scholarly articles in peer-reviewed journals.
We provide cutting-edge quantitative outcome analytics for clinical and preclinical researchers and sponsors. We combine standards-based approaches with research expertise to deliver accurate, precise measures in compliance with regulatory oversight.
A key part of our mission at BNAC is to teach. We disseminate knowledge and train future neuroimagers, trained masters, and PhD students. We host fellowships for visiting doctors and research scholars. BNAC faculty have mentored and co-mentored hundreds of PhD students, MSc students, MD students, undergraduate students, neuroimaging fellows, and neurology residents.
Precise, advanced neuroimaging metrics to measure treatment effects while maximizing statistical power.
Full coordination with participating imaging centers from study initiation, individual site on-boarding, image acquisition, and analysis.
Strict adherence to the highest standards and regulatory requirements, including FDA/EMA, GCP, and ISO 9001:2015.
Recently, several members of the BNAC team and their mentees have been honored by colleagues, the University at Buffalo, and the broader scientific community for exceptional work.
BNAC researchers and students join in celebrating the life and work of the late Lawrence Jacobs, BNAC founder and a brilliant and visionary biomedical researcher whose research changed forever how multiple sclerosis was treated around the world.
Atrophy or volume loss of the brain’s deep grey matter, and thalamic atrophy specifically, are strong drivers of worsening clinical disability and cognitive decline in people with multiple sclerosis (PwMS). A BNAC, investigator initiated study co-authored by Niels Bergsland, Ph.D., entitled, “Time course of lesion-induced atrophy in multiple sclerosis,” now provides a more precise understanding of when some of these impacts occur, improving our understanding of the pace of MS pathology.
The CASA-MS study’s Co-Investigator Dejan Jakimovski, Ph.D., recently spoke with some of the participants in the first-of-its-kind, investigator-initiated clinical trial that seeks answers for the 2.8 million MS patients who share the fear that their disease may accelerate at any time, leaving them completely dependent on care they may not be able to find or afford. “Will I just need a cane or a walker? Or will I become locked in my body until the end of my life?” WATCH THE FULL PRESENTATION.
Time Course of Lesion-induced Atrophy in Multiple Sclerosis.
-April 8, 2022
Cerebral Blood Flow Dependency on Systemic Arterial Circulation in Progressive Multiple Sclerosis.
-April 1, 2022
Functional Network Dynamics and Decreased Conscientiousness in Multiple Sclerosis.
-October 29, 2021
Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease.
-June 3, 2021
Director of IT and Neuroinformatics Development
BNAC Director
Director of Sequence Development
